Risk Factors for Progressive Supranuclear Palsy (PSP)

This study has been completed.
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Irene Litvan, University of Louisville
ClinicalTrials.gov Identifier:
First received: February 1, 2007
Last updated: July 3, 2013
Last verified: July 2013
Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian movement disorder. This study will determine the role of specific genetic, occupational and environmental components in the development of PSP by evaluating patients with this disorder and age and gender matched controls.

Progressive Supranuclear Palsy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Genetic and Environmental Risk Factors for PSP

Resource links provided by NLM:

Further study details as provided by University of Louisville:

Biospecimen Retention:   Samples With DNA
DNA will be used for genotyping specific genes of interest related to the disease.

Enrollment: 942
Study Start Date: August 2006
Study Completion Date: June 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
PSP Cases
Healthy Controls

Detailed Description:
This proposal will determine: (1) if there is an association between PSP and specific genes of interest; (2) if there is an association between PSP and occupational and/or environmental chemical exposures functionally or structurally similar to known parkinsonian toxicants; and (3) if hypertension or traumatic brain injury prior to symptom-onset is associated with PSP. To disentangle the complex etiology of PSP, this case-control multicenter study involves 500 PSP cases, 500 age/gender matched primary controls, and 500 secondary controls for genetic confirmation. Understanding the etiology of PSP may also help explain the causes of other related diseases such as Alzheimer's disease. This multidisciplinary team of movement disorder specialists, epidemiologists, geneticists, biostatisticians, industrial hygienist and toxicologist is well suited to unravel the etiology of PSP.

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with clinically diagnosed Progressive Supranuclear Palsy and healthy controls

Inclusion Criteria:

  • PSP patients able to visit one of the screening sites for diagnostic confirmation and able to participate in a one hour telephone interview

Exclusion Criteria:

  • No other major neurological disorders
  • Unable to communicate by telephone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00431301

United States, Alabama
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35233
United States, California
Los Angeles, California, United States, 90095-1759
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
United States, Georgia
Emory College of Medicine
Atlanta, Georgia, United States, 30322
United States, Illinois
Rush University
Chicago, Illinois, United States, 60611
United States, Kansas
University of Kansas
Kansas City, Kansas, United States, 66160
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
United States, Ohio
Case Western University
Cleveland, Ohio, United States, 44106
Canada, Ontario
University of Toronto
Toronto, Ontario, Canada, M5T 2S8
Sponsors and Collaborators
University of Louisville
National Institute on Aging (NIA)
Principal Investigator: Irene Litvan, M.D. University of Louisville
  More Information

Additional Information:
Responsible Party: Irene Litvan, Principle Investigator, University of Louisville
ClinicalTrials.gov Identifier: NCT00431301     History of Changes
Other Study ID Numbers: 1R01AG024040-01A2 
Study First Received: February 1, 2007
Last Updated: July 3, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Louisville:
Progressive Supranuclear Palsy
Neurodegenerative Disease
Movement Disorders
Atypical Parkinsonism
Parkinson Plus

Additional relevant MeSH terms:
Supranuclear Palsy, Progressive
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Cranial Nerve Diseases
Eye Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Ocular Motility Disorders
Signs and Symptoms

ClinicalTrials.gov processed this record on May 26, 2016